TheGridNet
The Vienna Grid Vienna

Vienna
Breaking News

Các nhà hàng Tin tức Radar thời tiết Danh-mục

Câu chuyện hàng đầu

Vienna Politics Tin tức

Vienna is establishing a service point in the city hall
Vienna is establishing a service point in the city hall
3 năm trước
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
3 năm trước
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 năm trước
Austria sees sharp rise in acts of antisemitism
Austria sees sharp rise in acts of antisemitism
3 năm trước
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
3 năm trước
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
3 năm trước
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 năm trước
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 năm trước
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 năm trước
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 năm trước